Mechanistically, we identified β2-adrenergic receptor (ADRB2) signaling as the pivotal molecular pathway driving stress-accelerated cancer progression, which was in line with the poor clinical outcomes observed in patients with cancer exhibiting enhanced adrenergic signaling within tumors. The gene discussed is ADRB2; the disease is cancer.